Cedars-Sinai Medical Center has entered into an agreement with Synthetic Biologics Inc. to conduct a clinical study of a drug to treat irritable bowel syndrome.
The Beverly Grove hospital announced the agreement Sept. 6 with the publicly owned San Diego biotech firm that holds an exclusive license to the drug developed at Cedars-Sinai.
The drug, known as SYN-010, is designed to reduce methane gas produced by microorganisms in the gut to treat an underlying cause of irritable bowel syndrome with constipation, or IBS-C.
“This research collaboration is a further demonstration of Cedars-Sinai’s support for the advancement of promising therapies that harness the power of the microbiome to treat GI disorders such as IBS-C,” said Dr. Mark Pimentel, a gastroenterologist at Cedars-Sinai and executive director of its Medical Associated Science and Technology program.
A phase 2 clinical study, co-funded by Cedars-Sinai and Synthetic Biologics, will take place at the hospital’s Pimentel Laboratory and may begin enrolling as many as 150 patients in the fourth quarter of this year.
Both Cedars-Sinai and Pimentel have a financial stake in Synthetic Biologics, according to the hospital.
The market for SN-010, a modified-release formulation of lovastatin, may include 45 million people in North America with irritable bowel syndrome.
Health business reporter Dana Bartholomew can be reached at email@example.com. Follow him on Twitter @_DanaBart.